Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 3(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03936361Phase 3Recruiting

Statins In Intracerbral Hemorrhage

Role: collaborator

NCT06897358Phase 2Active Not Recruiting

Leniolisib for Immune Dysregulation in CVID

Role: collaborator

NCT00745355Active Not Recruiting

Quality of Life in Patients With Bladder Cancer

Role: collaborator

NCT03200236Phase 3Completed

The Lung Screening, Tobacco and Health Project

Role: collaborator

All 4 trials loaded